FDA Rejects ImmunityBio’s Bladder Cancer Therapy, Sends Stock Tumbling | BioSpace

The regulator in a Complete Response Letter rejected ImmunityBio’s bladder cancer hopeful due to deficiencies with the company’s third-party contract manufacturer.

Read the full article here

Related Articles